1.Pharmacokinetics of mycophenolic acid in Chinese kidney transplant patients.
Xiao-Yang LU ; Hong-Feng HUANG ; Jian-Zhong SHENG-TU ; Jian LIU
Journal of Zhejiang University. Science. B 2005;6(9):885-891
To assess the influence of cyclosporin A (CsA) and tacrolimus (FK506) on mycophenolic acid (MPA) and correlation analysis of the pharmacokinetic parameters and patient characteristics, clinical outcome in Chinese kidney transplant recipients, the pharmacokinetics of 1000 mg mycophenolate mofetil (MMF) twice daily was measured by high-performance liquid chromatography (HPLC). PKS (Pharmaceutical Kinetics Software) 1.0.2 software package was used for the calculation of pharmacokinetic parameters. The mean C(max), t(max), and AUC((0-12))were (21.88+/-10.52) microg/ml, (1.20+/-0.95) h, and (52.546+/-13.215) microg.h/ml, respectively. The level of AUC((0-12)) in the FK506 group was significantly higher than that in the CsA group. MPA appeared not to be affected by renal function. MPA AUC((0-12)) showed statistically significant difference according to the patient's gender.
Adult
;
Cyclosporine
;
administration & dosage
;
Female
;
Humans
;
Immunosuppressive Agents
;
administration & dosage
;
pharmacokinetics
;
Kidney Transplantation
;
physiology
;
Male
;
Middle Aged
;
Mycophenolic Acid
;
administration & dosage
;
analogs & derivatives
;
pharmacokinetics
;
Tacrolimus
;
administration & dosage
2.Effect of local administration of cyclosporine A on peripheral nerve regeneration in a rat sciatic nerve transection model.
Rahim MOHAMMADI ; Hadi HEYDARIAN ; Keyvan AMINI
Chinese Journal of Traumatology 2014;17(1):12-18
OBJECTIVETo assess the effect of cyclosporine A (CsA) loaded in chitosan conduit on bridging the sciatic nerve defects in a rat model.
METHODSA 10 mm sciatic nerve defect was bridged using a chitosan conduit filled with 10 μl carrier-drug dilution (10 μg/L CsA). In control group, the conduit was filled with the same volume of carrier dilution alone. The regene-rated fibers were studied 4, 8 and 12 weeks after surgery.
RESULTSThe functional study confirmed faster recovery of the regenerated axons in treatment group than control group (P<0.05). There was statistically significant difference of the gastrocnemius muscle weight ratios between treatment and control groups (P<0.05). Morphometric indices of regenerated fibers showed that the number and diameter of the myelinated fibers in CsA-treated animals were significantly higher than those in control group. In immunohistochemistry, the location of reactions to S-100 in CsA group was clearly more positive than control group.
CONCLUSIONCsA loaded in a chitosan conduit results in improvement of functional recovery and quantitative morphometric indices of sciatic nerve. It is easily available without any complications compared with its systemic administration.
Animals ; Chitosan ; Cyclosporine ; administration & dosage ; pharmacology ; Immunohistochemistry ; Nerve Regeneration ; drug effects ; Rats ; Sciatic Nerve ; chemistry ; injuries
3.Immunosuppressive therapy for 54 children patients with acquired severe aplastic anemia.
Chun CHEN ; Jian-pei FANG ; Shao-liang HUANG ; Feng-yi ZHONG
Chinese Journal of Pediatrics 2006;44(11):841-844
OBJECTIVEAplastic anemia is characterized by bone marrow failure and marked reduction of white blood cells, red blood cells and platelets in peripheral blood. Clinical studies have shown that immunosuppressive therapy greatly prolonged the long-term survival of some patients with aplastic anemia. But in severe aplastic anemia (SAA) patients whose ANC was < 0.5 x 10(9)/L, platelets were < 20 x 10(9)/L, very low bone marrow proliferation and high death rate were observed. The present study aimed to evaluate the efficacy of immunosuppressive treatments with cyclosporine A (CSA) alone or CSA combined with antithymocyte globin (ATG) in children with acquired SAA.
METHODSFifty-four cases with SAA were treated with immunosuppressive agents mentioned above in our department from Jan. 1997 to June 2003, 31 of the cases had treated with CSA combined with ATG. There were 18 cases with SAA type I and 13 cases with SAA type II in CSA combined with ATG group, and 13 cases had very severe aplastic anemia. The other 23 cases were treated with CSA alone (CSA group), 10 of these cases had SAA-I and 13 had SAA-II, and 5 cases had very severe aplastic anemia. The responsive rate, relapse, adverse reactions and event free survival (EFS) were compared between CSA combined with ATG group and CSA group.
RESULTSThe proportions of patients with different types of the disease and severity were comparable between the two groups. The responsive time of the CSA combined with ATG group and CSA group was 2.5 months and 3.5 months, respectively (P < 0.05), the responsive rate in two groups was 81% (25/31) and 52% (12/23), respectively (chi(2) = 4.962, P < 0.05). In 37 cases who were responsive to therapy, the relapse rate was 8% (2/25) and 50% (6/12) respectively (chi(C)(2) = 6.143, P < 0.05). There were no significant differences in adverse reactions to the immunosuppressive agents. All cases were followed-up for more than 1 year, and the event-free survival over one year in these two groups was 81% (25/31) and 52% (12/23), respectively. Forty-seven cases were followed-up for more than two years, and the event-free survival was 74% (20/27) and 50% (10/20), respectively (P < 0.01). Twelve cases were followed-up for over 5 years. There were no secondary tumor, myelodysplastic syndrome and other colony diseases.
CONCLUSIONThe immunosuppressive therapies for acquired severe aplastic anemia in childhood were effective. The effect of CSA combined with ATG was better than that of CSA alone, and the relapse rate was lower with the combined treatment. However, the long-term effect needs longer follow-up studies to evaluate.
Adolescent ; Anemia, Aplastic ; drug therapy ; Antilymphocyte Serum ; administration & dosage ; therapeutic use ; Child ; Child, Preschool ; Cyclosporine ; administration & dosage ; therapeutic use ; Female ; Humans ; Immunosuppressive Agents ; administration & dosage ; therapeutic use ; Male
4.Study on preparation conditions for polylactide nanoparticles loaded cyclosporine A and its oral bioavailability in rats.
Xue-qing WANG ; Tao ZHANG ; Ying HE ; Liang ZHANG ; Qiang ZHANG
Acta Pharmaceutica Sinica 2004;39(1):68-71
AIMTo develop a less toxic alternative for sandimmun neoral (Neoral). To study the preparation conditions and to compare its pharmacokinetic characteristics with Neoral.
METHODSPolylactide nanoparticles loaded cyclosporine A was prepared by solvent-nonsolvent method. Polylactide nanoparticles were administered by oral in a dosage of 15 mg.kg-1. The CyA concentration in whole blood sample was determined by HPLC.
RESULTSThe quantities of CyA, PLA and volume of acetone added had significant influence on the NP diameters. Under proper condition, the nanoparticles with diameters of 57.5 nm were obtained. The relative bioavailability in rats was 101.6%, with a smaller absorption rate (P < 0.05) and a smaller elimination rate (P < 0.1).
CONCLUSIONThe nanoparticles (diamater < 100 nm) with relative high bioavailability were prepared using solvent-nonsolvent method. It is suitable for further study.
Administration, Oral ; Animals ; Biological Availability ; Cyclosporine ; administration & dosage ; pharmacokinetics ; Delayed-Action Preparations ; Immunosuppressive Agents ; administration & dosage ; pharmacokinetics ; Male ; Nanotechnology ; Polyesters ; Random Allocation ; Rats ; Rats, Wistar
5.Efficacy and safety of topical cyclosporine A 0.05% in vernal keratoconjunctivitis.
Ozlem Eski YÜCEL ; Nihal Demir ULUS
Singapore medical journal 2016;57(9):507-510
INTRODUCTIONWhile corticosteroids are an effective choice of treatment for severe vernal keratoconjunctivitis (VKC), their long-term use is restricted due to side effects. This study was conducted to evaluate the efficacy and safety of topical cyclosporine A (CsA) 0.05% in the treatment of VKC.
METHODSA total of 30 patients with VKC that was resistant to topical corticosteroids, antihistamines and mast cell stabilisers were treated with topical CsA 0.05%. Patients were evaluated at Weeks 4, 8 and 12 after the initiation of therapy. Symptoms and signs observed before and after treatment were recorded and scores were assigned. Scores for symptoms and signs, the need for topical corticosteroids and ocular side effects were evaluated.
RESULTSAt baseline, the median values of the symptom and sign scores were 10.0 (range 5.0-18.0) and 6.0 (range 2.0-13.0), respectively. At Week 4 of treatment with topical CsA 0.05%, the median values of the symptom and sign scores were 3.0 (range 0-14.0) and 3.0 (range 0-8.0), respectively. The reductions in the symptom and sign scores were statistically significant. The reduction in the need for corticosteroid was statistically significant by Week 12 of therapy. No significant side effects were reported.
CONCLUSIONTopical CsA 0.05%, which can help to reduce corticosteroid usage, is an effective and safe alternative for the treatment of resistant VKC. Further studies are needed to determine the optimal duration of therapy and possibility of recurrence.
Administration, Topical ; Adolescent ; Adrenal Cortex Hormones ; administration & dosage ; Adult ; Child ; Cohort Studies ; Conjunctivitis, Allergic ; drug therapy ; Cornea ; drug effects ; Cyclosporine ; administration & dosage ; Drug Administration Schedule ; Eye ; drug effects ; Female ; Humans ; Immunosuppressive Agents ; administration & dosage ; Male ; Recurrence ; Young Adult
6.A Case of Transmesocolic Hernia in Elderly Person without a History of Operation.
Hoon Suk PARK ; Jin Il KIM ; Myoung Seok KIM ; Soon Sub KIM ; Se Hyun CHO ; Soo Heon PARK ; Joon Yeol HAN ; Jae Kwang KIM
The Korean Journal of Gastroenterology 2006;48(4):286-289
Internal hernia is defined as the herniation of viscera through an anatomic or pathologic opening within the boundaries of peritoneal cavity. Transmesocolic hernia, a subtype of internal hernia, has a herniated sac through the transverse mesocolon. Transmesocolic hernia has been rarely described in the literature, and most of reported cases were associated with a history of operation or congenital anormaly. A 72-year-old female with chronic intermittent abdominal pain and bloating was admitted. Small bowel series showed multiple jejunal loops confined to the left upper quadrant of abdomen. Abdomen spiral computed tomography (CT) showed a cluster of mildly dilated small bowel loops with mesenteries on the same area. On the three-dimensional reconstruction CT scan, a herniated sac through the transverse mesocolon was identified. She was diagnosed as transmesocolic hernia by using the three-dimensional reconstruction CT and small bowel series, without surgical exploration. The symptoms were managed with conservative measures.
Colitis, Ulcerative/*drug therapy
;
Cyclosporine/*therapeutic use
;
Drug Tolerance
;
Humans
;
Hydrocortisone/administration & dosage/*therapeutic use
;
Injections, Intravenous
;
Methylprednisolone/administration & dosage/*therapeutic use
7.Effect of berberin hydrochloride on blood concentration of cyclosporine A in cardiac transplanted recipients.
Xue-shan HUANG ; Guo-feng YANG ; Yu-chen PAN
Chinese Journal of Integrated Traditional and Western Medicine 2008;28(8):702-704
OBJECTIVETo observe the clinic effect of combined use of berberin hydrochloride (Ber) with cyclosporine A (CsA) on the blood concentration of CsA in heart transplanted recipients.
METHODSThe blood concentration of CsA, liver-renal function and blood lipids in 22 heart transplanted recipients, who received Ber-CsA combined therapy, were measured.
RESULTSThe whole blood steady state concentration of CsA, C0 and C2, in recipients after being treated with Ber-CsA significantly increased than those before applying Ber-CsA (P < 0.01), with the mean increment of 26% and 18% respectively; the dosage of CsA used decreased in 21 patients by 25-100 mg/d; and the Ber-CsA showed no significant effect on liver-renal function or blood lipids (P > 0.05).
CONCLUSIONCombined use of CsA with Ber could markedly increase the blood concentration of CsA in heart transplanted recipients and reduce the dosage of CsA required, save the fee for medical service, and shows no obvious adverse reaction.
Adolescent ; Adult ; Aged ; Berberine ; administration & dosage ; Cyclosporine ; administration & dosage ; blood ; Drug Therapy, Combination ; Female ; Graft Rejection ; blood ; drug therapy ; Heart Transplantation ; Humans ; Male ; Middle Aged ; Young Adult
8.Clinical report on treatment of 7 patients with refractory anemia by using cyclosporin A.
Xiang-Rong KONG ; Yi-Ming FENG
Journal of Experimental Hematology 2004;12(5):697-698
To explore the treatment of refractory anemia (RA), 7 cases of myelodysplastic syndrome (subtype of refractory anemia) were treated in combination of cyclosporin A (CsA) with stanozolol. Duration of treatment with CsA was 5 months-3 years (mean 13 months). The results showed that among 7 cases 6 were effective, 1 case no responded to treatment. 3 cases out of 6 effective cases achieved complete remission without transfusion dependence, 1 cases achieved partial remission, 2 cases were improved. During the investigation signs of leukemia ot other malignant tumors not were found in all cases. In conclusion, CsA treatment is effective for part cases of RA, side effects of drugs are tolerable for patients.
Adolescent
;
Adult
;
Aged
;
Anemia, Refractory
;
drug therapy
;
Cyclosporine
;
administration & dosage
;
Drug Therapy, Combination
;
Female
;
Humans
;
Male
;
Middle Aged
;
Stanozolol
;
administration & dosage
9.Clinical Efficacy Comparison of Ultralow Dose of Decitabine and Cyclosporine on Low-risk and Intermediate-risk Type 1 of Myelodysplastic Syndrome.
Xiu LUO ; Hao WU ; Yi DING ; Yu-Hua CHEN ; Ai-Bin LIANG
Journal of Experimental Hematology 2016;24(2):510-514
OBJECTIVETo evaluate the clinical efficacy and safety of decitabine and cyclosporine for treatment of low-risk and intermediate-risk-1 myelodysplastic syndrome (MDS) patients.
METHODSThe clinical data of 27 cases of low risk and intermediate-risk-1 MDS during the past 3 years in Tongji hospital were analyzed retrospectively. These MDS patients were divided into 2 groups: decitabine group (11 cases) and cyclosporine group (16 cases). The MDS patients in the 2 groups were treated with ultra low dose of decitabine and cyclosporine A; the curetive efficacy and adverse reactions were evaluated.
RESULTSIn the 11 patients with low-risk and intermediate-risk-1 MDS treated with 2 courses of ultra-low-dose decitabine, 4 cases (36.4%) achieved a hematological improvement, 7 cases (63.6%) showed ineffective, including non-remission in 6 cases (54.5 %) and death in 1 patient (9.1%), total effective rate were 36.4%; 3 cases died within the first year and the overall survival (OS) rate was 72.7%. The causes of death mainly were severe myelosuppression and the associated infection and bleeding. In the 16 patients with low-risk and intermediate-risk-1 MDS treated with cyclosporine (CsA), 10 cases (62.5%) achieved a hematological improvement, 6 cases (37.5%) showed ineffective, the total efficiency of 62.5%; no patients died within 1 year, the 1-year OS was 100%. Changes in neutrophils, hemoglobin and platelet were not significantly different between the two group.
CONCLUSIONThe clinical efficacy of decitabine on low-risk and intermediate-risk-1 MDS has not confirmed to be superior to cyclosporine (P = 0.252). However, the side effects of serious infection and myelosuppression were more severe in decitabine group than that in the cyclosporine group. Moreover, the 1-year overall survival rate in decitabine group is much lower than that in the cyclosporine group (P = 0.027). In regard to the small number of cases and short follow-up time in our this study, the more patients and longer follow-up time are needed to study.
Azacitidine ; administration & dosage ; analogs & derivatives ; therapeutic use ; Cyclosporine ; administration & dosage ; therapeutic use ; Humans ; Myelodysplastic Syndromes ; drug therapy ; Pancytopenia ; Retrospective Studies ; Survival Rate ; Treatment Outcome
10.Cyclosporine A in treatment of membranous lupus nephropathy.
Weixin HU ; Zhihong LIU ; Shuqiong SHEN ; Shijun LI ; Xiaodan YAO ; Huiping CHEN ; Leishi LI
Chinese Medical Journal 2003;116(12):1827-1830
OBJECTIVETo investigate retrospectively the efficacy of cyclosporine A (CsA) in the treatment of membranous lupus nephropathy (MLN).
METHODSTwenty-four patients with systemic lupus erythematosus (SLE) and biopsy-proven MLN were treated with CsA in combination with prednisone. CsA was given at a starting dosage of 5 mg x kg(-1) x d(-1) for 3 months, with a 1 mg x kg(-1) x d(-1) reduction every month and then maintained at a dosage of 2 mg x kg(-1) x d(-1). The dosage of oral prednisone differed from person to person according to levels of extra-renal activity. Clinical efficacy and adverse reactions were retrospectively analyzed. Complete remission was defined as having a urinary proteinuria level (Upr) of < 0.4 g/d, and normal serum albumin and serum creatinine (SCr) levels, without SLE activity. Partial remission was defined as having a UPr decrement > 50% of baseline value and a serum albumin value of 30 - 35 g/L, without SLE activity. No response was defined as having a Upr decrement < 50% of baseline value and > 2.0 g/d, or as a deterioration of renal function, or as having active SLE.
RESULTSOne patient could no longer undergo follow-up, and the other 23 patients were treated with CsA and followed up for 6 - 36 months (mean 16.8 +/- 8.4 months). The mean starting dosage of CsA was 4.7 +/- 0.5) mg x kg(-1) x d(-1) and the trough level of the whole blood CsA was 248 +/- 110) micro g/L. Twelve patients (52.2%) achieved complete remission, 10 patients (43.3%) achieved partial remission after CsA treatment, and one patient showed no response. At different CsA treatment timepoint, the complete remission rates were 17.4% (3rd month), 21.7% (6th month), 40% (12th month), 88.9% (18th month) and 100% (24th month) respectively. SCr elevation, when within a normal limit was not observed in most patients during early CsA administration, and at the end of the follow-up all the patients had a normal SCr. Relapse occurred in 33.3% of the patients after withdrawing CsA for 4 - 24 months. No chronic CsA renal toxicity was observed in 4 patients who had a repeat renal biopsy after CsA treatment for 6 - 24 months.
CONCLUSIONSCsA could be regarded as an effective therapy for patients with membranous lupus nephropathy, but its adverse effects, especially its nephrotoxicity, should be carefully monitored during CsA treatment.
Adolescent ; Adult ; Cyclosporine ; administration & dosage ; therapeutic use ; Female ; Glomerulonephritis, Membranous ; drug therapy ; Humans ; Lupus Nephritis ; drug therapy ; Male ; Prednisone ; administration & dosage ; Retrospective Studies ; Treatment Outcome